 SHELTON, CT ACCESSWIRE March 9, 2021 NanoViricides, Inc. NYSE American: NNVC the Company, a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection. The Company is preparing a pre-IND application encompassing its two clinical drug candidates for the treatment of COVID-19 infected patients. 